Brief: Neurotech International Gets US FDA Rare Pediatric Disease Designation For NTI164
08/10/2025 02:26
Oct 8 (Reuters) - Neurotech International Ltd NTI.AX: US FDA RARE PEDIATRIC DISEASE DESIGNATION FOR NTI164 IN RETT SYNDROME Further company coverage: NTI.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurotech International
See all newsBrief: Neurotech International Says Anthony Filippis Resigns As CEO, MD
Brief: Neurotech International Appoints Mark Davies As Executive Chairman
Brief: Neurotech International Receives Binding Commitments For Around A$4.50 Million In Placement At A$0.014 Per Share
Australia's Neurotech International slips to a month low on discounted placement
Brief: Neurotech International Requests Trading Halt